Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06210815 Recruiting - Solid Tumor Clinical Trials

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

NCT ID: NCT06209385 Recruiting - Solid Tumor Clinical Trials

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Start date: August 11, 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors

NCT ID: NCT06208878 Enrolling by invitation - Clinical trials for Hematologic Malignancy

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Start date: November 22, 2023
Phase:
Study type: Observational

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

NCT ID: NCT06208657 Not yet recruiting - Childhood Cancer Clinical Trials

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A companion platform trial to test novel targeted agents based on the patient's tumor profile.

NCT ID: NCT06208410 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.

NCT ID: NCT06208371 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

Start date: January 15, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.

NCT ID: NCT06207864 Recruiting - Malignant Neoplasm Clinical Trials

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

PE-CGS
Start date: March 22, 2022
Phase: N/A
Study type: Interventional

This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.

NCT ID: NCT06207032 Recruiting - Cancer Clinical Trials

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Start date: June 1, 2024
Phase:
Study type: Observational

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

NCT ID: NCT06206915 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Study of XZ120 in Malignant Tumors

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.

NCT ID: NCT06206863 Recruiting - Clinical trials for Malignant Solid Neoplasm

Community-Based Physical Activity Intervention for Underserved Cancer Survivors

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. Historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. In this study, researchers have partnered with the YMCA to provide tailored home-based exercise programs for underserved cancer patients and survivors. Accessing exercise professionals may allow patients to prevent acute problems from becoming chronic, long-lasting physically weak impairments that directly influence patients' quality of life.